Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's stock has risen by 40.32% in the last six months and 10.10% over the past year, closing at $785.51 on February 6, 2026. Recent earnings reports have been a significant driver, with Q4 2025 EPS and revenue exceeding analyst estimates due to strong Dupixent sales and EYLEA HD traction. Analysts have reiterated "Buy" ratings and raised price targets. However, sales of legacy EYLEA are declining due to competition and affordability issues. The company faces risks with development programs and an FDA delay for the EYLEA HD pre-filled syringe. Regeneron's 2026 guidance indicates higher expenditures, suggesting near-term margin pressure, and they are negotiating U.S. drug-pricing measures.

Demand seasonality for Regeneron Pharmaceuticals' products can be observed, with some products experiencing "typical seasonality dynamics." First-quarter results for some products reflect these seasonal patterns and the timing of shipments and inventory levels. The company's overall stock performance can be analyzed for historical seasonal patterns to identify recurring monthly trends.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for serious medical conditions, operating within the biotechnology sector and pharmaceutical preparations industry. They develop products for therapeutic areas including allergic and inflammatory diseases, eye diseases, cancer, and infectious diseases. Regeneron's portfolio includes drugs like Eylea and Dupixent and they developed REGEN-COV for COVID-19. They partner with companies like Sanofi and Bayer for product development and utilize VelociSuite technologies for antibody drug development. In 2023, Regeneron invested $4.4 billion in R&D and has over 30 programs in clinical development.

Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, and has a global presence with offices in 12 countries and clinical trials in over 50 countries. Key geographic regions include North America, Europe, and Asia. The company's asset turnover ratio in the United States fluctuated, while the "Rest of World" segment showed an upward trend in asset utilization from 2022 to 2024.

Regeneron's brand reputation has been positively influenced by the strong sales growth of Dupixent and EYLEA HD, as well as its commitment to scientific innovation and robust pipeline. Challenges with the legacy EYLEA product and the delay in FDA approval for the EYLEA HD pre-filled syringe have presented some reputational challenges. Analyst ratings generally remain positive, with a consensus "Buy" rating from 20 analysts as of February 6, 2026.

Regeneron Pharmaceuticals has a significant institutional ownership base, with 2052 institutional owners and shareholders holding a total of 103,432,704 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. As of September 30, 2025, The Vanguard Group, Inc. held 8.82% of the company's shares, followed by BlackRock, Inc. with 8.60%, and State Street Global Advisors, Inc. with 4.57%.